Tag: Cancer: Kidney
Immunotherapy Combo Treats Advanced Kidney Cancer
First results show survival benefit with nivolumab plus cabozantinib versus sunitinib
Percutaneous Cryoablation Treats Early-Stage Kidney Cancer
10-year disease-specific survival 94 percent; 10-year risk for hemodialysis only 2.3 percent
Acute Kidney Injury Seems to Promote Renal Cell Carcinoma
AKI promotes the development of papillary renal cell carcinoma from single progenitors
Chemo Ups Disease-Free Survival in Upper Tract Urothelial Cancer
Gemcitabine-platinum combination therapy tied to improved survival after nephroureterectomy
Tivozanib Bests Sorafenib in Metastatic Renal Cell Carcinoma
Progression-free survival longer in those receiving tivozanib as third- or fourth-line therapy
Acute Kidney Injury Often Seen With Checkpoint Inhibitor Use
8 percent of patients receiving checkpoint inhibitor therapy experienced sustained acute kidney injury
Study Reveals Lower Predictive Ability for Renal Cancer Models
Prospective validation shows decrease in predictive ability compared with previous retrospective validations
Avelumab + Axitinib Approved for Treatment of Renal Cell Carcinoma
Treatment combination demonstrated longer progression-free survival versus sunitinib in randomized trial
FDA Approves Pembrolizumab Plus Axitinib for Advanced RCC
Drug combination approved for advanced renal cell carcinoma based on findings from KEYNOTE-426
Extra Weight in Adolescence Tied to Later Risk for Renal Cancer
Among Swedish men, overweight or obesity during adolescence tied to higher risk for renal cell carcinoma
